SPARCC MRI Scoring in Axial Spondyloarthritis: A Comprehensive Review
Abstract
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints (SIJs) and spine, with significant diagnostic challenges due to nonspecific early symptoms and limited radiographic evidence. The Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scoring system provides a standardized, reproducible method for quantifying bone marrow edema (BME) severity in SIJs.
Objective: This review synthesizes current evidence on the diagnostic utility of SPARCC MRI scoring, with particular emphasis on recent validation studies in understudied populations, optimal cutoff values for identifying high disease activity, and the unique epidemiological and immunogenetic considerations of the Middle East and North Africa (MENA) region.
Methods: This narrative review draws upon a recent prospective cross-sectional study conducted at Zagazig University, Egypt, alongside contemporary international literature on SPARCC validation, treat-to-target strategies, and regional disease characteristics.
Results: SPARCC scores demonstrate strong correlations with objective inflammatory markers (ESR, CRP) and composite disease activity indices (ASDAS-ESR, ASDAS-CRP), with the highest reported correlation being r = 0.929 for ASDAS-ESR. ROC analysis consistently yields excellent diagnostic accuracy (AUC > 0.94) for identifying high disease activity, with an optimal cutoff of ≥5 achieving 100% sensitivity, 77.3% specificity, and 91.7% accuracy. The MENA region exhibits markedly lower HLA-B27 positivity rates (11.7–65%) compared to Northern European populations (>90%), necessitating region-specific diagnostic algorithms.
Conclusion: SPARCC MRI scoring is a valid and clinically useful tool for assessing SIJ inflammation across diverse populations. The SPARCC ≥5 cutoff supports its integration into disease assessment and treatment decision-making, particularly in resource-limited settings where MRI access may be constrained. Future longitudinal studies are needed to validate treatment response monitoring and structural progression prediction in MENA populations.